Articles by Jamile Shammo, MD
Is ESA use and performance in the academic setting reflective of real-world MDS practice? Our expert panel discusses.
The panel discusses how to best implement such a monitoring system to address a widespread issue of suboptimal dosing.
The panel led by Jamile Shammo, MD, reacts to results from a claims database study comparing the agent with ESAs.
The expert panel discussion led by Jamile Shammo, MD, also noted differences in cell line suppression by mutational profile.
Jamile Shammo, MD, leads a roundtable discussion on the effect of molecular data incorporation and goals in treatment.
The expert panel led by Jamile Shammo, MD, tells how trial data and their clinical experiences inform their use of the agent.
Dr. Shammo gives her impressions of how growing incorporation of MDS molecular data is changing disease management.
The panel mainly focused on how to define and classify MDS and CHIP, as well as how to treat low- and high-risk MDS.
HMAs such as decitabine and cedazuridine (Inqovi) have become the “cornerstone” of treating high-risk patients.
The panel shares their outlook for the future of MDS research and treatment.
Dr. Tanaka outlines a biomarker study that observed reduced inflammation in patients with MDS treated with luspatercept.
The panel discussed a study that assessed quality of life and PROs in patients receiving luspatercept for MDS.
The panel discusses whether starting treatment with luspatercept sooner in patients with MDS is beneficial.
Dr. Shammo shares her reaction to a study that assessed mutational burden and impact on primary outcomes in COMMANDS.
Dr. Safah outlines the findings from the full analysis of the COMMANDS trial.
The panel discusses the evolution of MDS therapy.
Dr. Safah gave an overview of myelodysplastic syndromes.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.